Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Caladrius Biosciences
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / It was a day of big gains for biotech stocks Sarepta Therapeutics and Caladrius Biosciences on Tuesday. Sarepta soared almost 37% on positive interim data on its gene therapy to help patients with Duchenne muscular dystrophy while Caladrius Biosciences skyrocketed over 67% after announcing RMAT designation from the FDA for its late-stage CD34+cell therapy program for the treatment of refractory angina, regenerative.
RDI Initiates Coverage on:
Sarepta Therapeutics, Inc.
https://www.rdinvesting.com/report/?ticker=SRPT
Caladrius Biosciences, Inc.
https://www.rdinvesting.com/report/?ticker=CLBS
Sarepta Therapeutics, Inc. shares closed up nearly 37% on Tuesday with about 15 million shares traded. The stock hit a brand new high of $176.50 after the company announced that study results showed that a gene therapy helped patients with Duchenne muscular dystrophy significantly reduce levels of creatine kinase, an enzyme associated with muscle damage caused by the disorder. Positive interim data for the experimental gene therapy AAVrh74.MHCK7.micro-Dystrophin, also showed that the therapy increased the levels of a missing structural protein in the first three patients in the study. The protein is largely absent in the muscles of patients suffering from Duchenne muscular dystrophy. ''I have been waiting my entire 49-year career to find a therapy that dramatically reduces [creatine kinase] levels and creates significant levels of dystrophin,'' remarked Dr. Jerry Mendell, the study's principal investigator. ''Although the data are early and preliminary, these results, if they persist and are confirmed in additional patients, will represent an unprecedented advancement in the treatment of DMD," he continued.
Access RDI's Sarepta Therapeutics, Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=SRPT
Caladrius Biosciences, Inc. shares closed up a little over 67% on Tuesday on colossal trading volume compared to usual. The stock traded nearly 3.3 million shares compared to an average trading volume of about 28,000 shares. The clinical-stage biopharma company announced that the FDA has granted the Company's late-stage CD34+ cell therapy program for the treatment of refractory angina, regenerative medicine advanced therapy (RMAT) designation. President and CEO of the company, David J. Mazzo, Ph.D., commented, "We are delighted and encouraged that the FDA has recognized our CD34+ cell therapy program with an RMAT designation. Refractory angina is a serious condition with high morbidity and no known effective treatments. We look forward to working with the FDA to define a path to registration for our therapy with the aim of providing expeditious treatment to patients suffering from this condition."
Access RDI's Caladrius Biosciences, Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=CLBS
Our Actionable Research on Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and Caladrius Biosciences, Inc. (NASDAQ: CLBS) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
